In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a ...

Chris Schott, an analyst from J.P. Morgan, maintained the Buy rating on Eli Lilly & Co (LLY – Research Report). The associated price target ...

Indianapolis-based Eli Lilly and Co. will begin studies to see if its blockbuster weight-loss medicines are also effective at controlling addictive behaviors such alcohol abuse, smoking and drug ...

The U.S. Food and Drug Administration has approved Eli Lilly and Co.’s obesity-treatment Zepbound as the first medicine for adults with moderate-to-severe obstructive sleep apnea and obesity.

About half the savings would be put toward new medicines. Eli Lilly, based in Indiana, employed more than 41,000 people globally at the end of June. Like other US pharmaceutical companies ...

For a drug that has been on the market for only a year, Eli Lilly and Co.’s anti-obesity treatment Zepbound has quickly made a huge name for itself, racking up more than $3 billion in sales and ...

Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli ... 1 drugs. Lilly’s Zepbound, approved in November 2023 as the Indiana ...

Eli Lilly estimates that is about 15-20 million adults in the U.S. Obstructive sleep apnea isnt just an inconvenience, its a serious medical condition that impairs breathing and sleep quality.